nach oben

Acta Neuropathologica

Erschienen in:

01.01.2010 | Correspondence

The neuropathologic substrate of Parkinson disease dementia

verfasst von: Kurt A. Jellinger

Erschienen in: Acta Neuropathologica | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Excerpt

In their recent review about the morbid anatomy of dementia, Kalaitzakis and Pearce [24] critically discussed the impact of both cortical α-synuclein (αSyn) and Alzheimer disease (AD) pathologies and the molecular interactions between αSyn, tau, and Aβ proteins in the development of cognitive impairment in Parkinson disease (PD), suggesting a linked pathological cascade of AD- and PD-related mechanisms. This commentary is intended (1) to confirm most of the statements of this review and (2) to add some personal and further recent data about the very complex relations between cognitive impairment and neuropathology in Lewy body diseases. …

Aho L, Parkkinen L, Pirttila T, Alafuzoff I (2008) Systematic appraisal using immunohistochemistry of brain pathology in aged and demented subjects. Dement Geriatr Cogn Disord 25:423–432CrossRefPubMed

Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW (2002) Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 59:102–112CrossRefPubMed

Barrachina M, Dalfo E, Puig B, Vidal N, Freixes M, Castano E, Ferrer I (2005) Amyloid-beta deposition in the cerebral cortex in dementia with Lewy bodies is accompanied by a relative increase in AbetaPP mRNA isoforms containing the Kunitz protease inhibitor. Neurochem Int 46:253–260CrossRefPubMed

Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL 3rd, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117:613–634CrossRefPubMed

Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64:1404–1410PubMed

Brooks DJ (2009) Imaging amyloid in Parkinson’s disease dementia and dementia with Lewy bodies with positron emission tomography. Mov Disord 24(Suppl 2):S742–S747PubMedCrossRef

Colosimo C, Hughes AJ, Kilford L, Lees AJ (2003) Lewy body cortical involvement may not always predict dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 74:852–856CrossRefPubMed

Deramecourt V, Bombois S, Maurage CA, Ghestem A, Drobecq H, Vanmechelen E, Lebert F, Pasquier F, Delacourte A (2006) Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. J Neuropathol Exp Neurol 65:278–288PubMed

Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I (2010) Diagnostic criteria for the neuropathological assessment of Parkinson disease: report of the neuropathology and genetics working group of the second international brainstorming conference on Parkinson disease. Lancet Neurol (in press)

10.

Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O’Keefe G, Nagren K, Chaudhury KR, Masters CL, Brooks DJ (2008) Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79:1331–1338CrossRefPubMed

11.

Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathis CA, Elmaleh DR, Shoup T, Fischman AJ, Hyman BT, Growdon JH, Johnson KA (2008) Imaging amyloid deposition in Lewy body diseases. Neurology 71:903–910CrossRefPubMed

12.

Harding AJ, Halliday GM (2001) Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 102:355–363PubMed

13.

Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23:837–844CrossRefPubMed

14.

Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE (2000) Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 54:1916–1921PubMed

15.

Jellinger KA, Seppi K, Wenning GK, Poewe W (2002) Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm 109:329–339CrossRefPubMed

16.

Jellinger KA (2007) Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. J Neural Transm Suppl 72:91–104CrossRefPubMed

17.

Jellinger KA (2008) Re: In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology 70:407–408CrossRefPubMed

18.

Jellinger KA (2008) A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 116:1–16CrossRefPubMed

19.

Jellinger KA, Attems J (2008) Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 115:127–136CrossRef

20.

Jellinger KA (2009) Editorial: The neurological substrate of Parkinson disease dementia. J Mov Disord 23:1–3

21.

Jellinger KA (2009) Significance of brain lesions in Parkinson disease dementia and Lewy body dementia. In: Giannakopoulos P, Hof PR (eds) Dementia in clinical practice. Front Neurol Neuroscience, vol 24. Karger, Basel, pp 114–125

22.

Jellinger KA (2009) A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 1792:730–740PubMed

23.

Jendroska K, Lees AJ, Poewe W, Daniel SE (1996) Amyloid beta-peptide and the dementia of Parkinson’s disease. Mov Disord 11:647–653CrossRefPubMed

24.

Kalaitzakis ME, Pearce RK (2009) The morbid anatomy of dementia in Parkinson’s disease. Acta Neuropathol 118:587–598CrossRefPubMed

25.

Kovari E, Gold G, Herrmann FR, Canuto A, Hof PR, Bouras C, Giannakopoulos P (2003) Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson’s disease. Acta Neuropathol (Berl) 106:83–88

26.

Lashley T, Holton JL, Gray E, Kirkham K, O’Sullivan SS, Hilbig A, Wood NW, Lees AJ, Revesz T (2008) Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson’s disease patients. Acta Neuropathol 115:417–425CrossRefPubMed

27.

Maetzler W, Reimold M, Liepelt I, Solbach C, Leyhe T, Schweitzer K, Eschweiler GW, Mittelbronn M, Gaenslen A, Uebele M, Reischl G, Gasser T, Machulla HJ, Bares R, Berg D (2008) [11C]PIB binding in Parkinson’s disease dementia. Neuroimage 39:1027–1033CrossRefPubMed

28.

Mastaglia FL, Johnsen RD, Byrnes ML, Kakulas BA (2003) Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson’s disease. Mov Disord 18:81–86CrossRefPubMed

29.

Mattila PM, Rinne JO, Helenius H, Roytta M (1999) Neuritic degeneration in the hippocampus and amygdala in Parkinson’s disease in relation to Alzheimer pathology. Acta Neuropathol (Berl) 98:157–164CrossRef

30.

Mattila PM, Rinne JO, Helenius H, Dickson DW, Roytta M (2000) Alpha-Synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease. Acta Neuropathol 100:285–290CrossRefPubMed

31.

Oinas M, Polvikoski T, Sulkava R, Myllykangas L, Juva K, Notkola IL, Rastas S, Niinisto L, Kalimo H, Paetau A (2009) Neuropathologic findings of dementia with Lewy bodies (DLB) in a population-based Vantaa 85+ study. J Alzheimers Dis 18:677–689PubMed

32.

Parkkinen L, Soininen H, Laakso M, Alafuzoff I (2001) Alpha-synuclein pathology is highly dependent on the case selection. Neuropathol Appl Neurobiol 27:314–325CrossRefPubMed

33.

Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I (2005) Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57:82–91CrossRefPubMed

34.

Parkkinen L, Pirttila T, Alafuzoff I (2008) Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 115:399–407CrossRefPubMed

35.

Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Vedders L, Peterson LK, Caviness JN, Shill HA, Sue LI, Ziabreva I, Perry E, Ballard CG, Aarsland D, Walker DG, Beach TG (2009) Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 23:295–297CrossRefPubMed

36.

Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ (2009) A clinico-pathological study of subtypes in Parkinson’s disease. Brain 132:2947–2957CrossRefPubMed

37.

Soto C, Estrada LD (2008) Protein misfolding and neurodegeneration. Arch Neurol 65:184–189CrossRefPubMed

38.

Strobel G (2009) Meeting report: the spectrum series: grappling with the overlap between Alzheimer’s and Parkinson’s diseases. J Alzheimers Dis 18:625–640PubMed

39.

Thomas A, Ballard C, Kenny RA, O’Brien J, Oakley A, Kalaria R (2005) Correlation of entorhinal amyloid with memory in Alzheimer’s and vascular but not Lewy body dementia. Dement Geriatr Cogn Disord 19:57–60CrossRefPubMed

40.

Wu E, Lipton RB, Dickson DW (1992) Amyloid angiopathy in diffuse Lewy body disease. Neurology 42:2131–2135PubMed

Titel: The neuropathologic substrate of Parkinson disease dementia
verfasst von: Kurt A. Jellinger
Publikationsdatum: 01.01.2010
Verlag: Springer-Verlag
Erschienen in: Acta Neuropathologica / Ausgabe 1/2010
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-009-0613-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update

Sialidosis type I carrying V217M/G243R mutations in lysosomal sialidase: an autopsy study demonstrating terminal sialic acid in lysosomal lamellar inclusions and cerebellar dysplasia

The enigmatic roles of microglial versus neuronal progranulin in neurological disease

Progranulin expression is upregulated after spinal contusion in mice

Brain progranulin expression in GRN-associated frontotemporal lobar degeneration